Brief: Heron Therapeutics Inc U.S. District Court Upholds Validity Of Cinvanti Patents
03/12/2024 22:56
Dec 3 (Reuters) - Heron Therapeutics Inc HRTX.O :
* HERON THERAPEUTICS INC: U.S. DISTRICT COURT UPHOLDS
VALIDITY OF
CINVANTI PATENTS
* HERON THERAPEUTICS- U.S. DISTRICT COURT RULED IN CO'S
FAVOR IN
PATENT LITIGATION AGAINST FRESENIUS KABI USA RELATED TO CINVANTI
* HERON THERAPEUTICS-WILL SEEK ORDER FROM U.S. COURT
PROHIBITING
FRESENIUS FROM LAUNCHING ITS GENERIC CINVANTI UNTIL AFTER
EXPIRATION OF PATENTS IN 2035
Source text: ID:nPn9N1ljla
Further company coverage: HRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Heron Therapeutics
See all newsHeron Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Heron Therapeutics Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: U.S. District Court Issues Decision Regarding CINVANTI Patents
Heron Therapeutics' Q1 revenue falls as oncology sales drop